Atea Pharmaceuticals, Inc. (AVIR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 18, 2026, details the results of Atea Pharmaceuticals, Inc.'s 2026 Annual Meeting of Stockholders. The meeting was held on June 18, 2026, with 59,742,819 shares present in person or by proxy, representing approximately 74.65% of the common stock outstanding as of the April 24, 2026 record date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The following proposals were voted upon and approved by the stockholders:
- Proposal 1 (Election of Directors): Three Class III directors were elected to serve until the 2029 annual meeting.
- Jerome Adams, MD, MPH: 28,798,012 votes FOR; 22,275,665 votes WITHHOLD.
- Howard Berman, PhD: 44,466,627 votes FOR; 6,607,050 votes WITHHOLD.
- Barbara Duncan: 43,697,098 votes FOR; 7,376,579 votes WITHHOLD.
- Proposal 2 (Ratification of Auditors): Ratification of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026.
- Result: 58,894,207 votes FOR; 783,081 votes AGAINST; 65,531 votes ABSTAIN.
- Proposal 3 (Executive Compensation): Advisory approval of the compensation of named executive officers.
- Result: 47,452,759 votes FOR; 2,977,290 votes AGAINST; 643,628 votes ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the certification of voting results.
Key Facts for Investor Verification
- Verify the specific terms of the director elections, noting that Dr. Jerome Adams received a significant number of "Withhold" votes compared to the other nominees.
- Confirm the appointment of KPMG LLP as the auditor for the fiscal year ending December 31, 2026.
- Review the definitive proxy statement (Schedule 14A) filed on April 27, 2026, for detailed descriptions of the proposals and executive compensation details.
- Note that 8,669,142 shares were recorded as "Broker Non-Votes" for the director election and executive compensation proposals.